Ignite Creation Date:
2024-05-06 @ 3:09 AM
Last Modification Date:
2024-10-26 @ 11:29 AM
Study NCT ID:
NCT02213744
Status:
TERMINATED
Last Update Posted:
2017-01-06
First Post:
2014-08-06
Brief Title:
MM-302 Plus Trastuzumab vs Chemotherapy of Physicians Choice Plus Trastuzumab in HER2-Positive Locally AdvancedMetastatic Breast Cancer Patients
Sponsor:
Merrimack Pharmaceuticals
Organization:
Merrimack Pharmaceuticals
Conditions & Keywords Data
Conditions:
| Name |
|---|
| HER2 Positive Breast Cancer |
| Breast Cancer |